<DOC>
	<DOCNO>NCT01213992</DOCNO>
	<brief_summary>The purpose study assess pharmakokinetic property higher dos ( 500 mg 1000 mg ) Monofer® patient suffer Non-dialysis Dependent Chronic Kidney Disease .</brief_summary>
	<brief_title>Open-label Pharmacokinetic Study Iron Isomaltoside 1000 ( Monofer® ) Administered 500 mg IV Bolus Injection 1000 mg Intravenous Patients With CKD</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Men woman , age 18 year . 2 . Weight 50 kg . 3 . Subjects diagnose NDDCKD MDRD calculate eGFR 1559 mL/min . 4 . Hb &lt; 11.0 g/dL . 5 . Either follow iron store indicator target { Serum ferritin &lt; 100 ug/l Transferrin saturation ( TfS ) &lt; 20 % } . 6 . Life expectancy beyond 12 month Principal Investigator 's judgement . 7 . Willingness participate inform consent . 1 . Anaemia predominantly cause factor renal impairment iron deficiency ( accord Principal Investigator ' judgment ) . 2 . Iron overload disturbance utilization iron ( e.g . haemochromatosis haemosiderosis ) . 3 . Drug hypersensitivity ( i.e . previous hypersensitivity iron dextran iron mono disaccharide complex excipients study drug ) . 4 . Subjects history multiple allergy . 5 . Decompensated liver cirrhosis hepatitis ( alanine aminotransferase ( ALT ) &gt; 3 time upper normal limit ) . 6 . History Immunocompromise and/or history Hepatitis B and/or C 7 . Active acute chronic infection ( assessed clinical judgment ) , supply white blood cell ( WBC ) Creactive protein ( CRP ) . 8 . Rheumatoid arthritis symptom sign active joint inflammation . 9 . Pregnancy nursing ( To avoid pregnancy , woman postmenopausal ( least 12 month must elapse since last menstruation ) , surgically sterile , woman child bear potential must use one follow contraceptive whole study period study end least 5 time plasma biological halflife investigational medicinal product : Contraceptive pill , intrauterine device ( IUD ) , contraceptive depot injection ( prolongedrelease gestagen ) , subdermal implantation , vaginal ring , transdermal patch ) . 10 . Extensive active bleeding necessitate blood transfusion . 11 . Planned elective surgery study . 12 . Participation clinical study within 3 month prior screen . 13 . Untreated B12 folate deficiency . 14 . Other I.V . oral iron treatment blood transfusion within 4 week prior screen visit . 15 . ESA treatment within 8 week prior screen visit . 16 . Serum Ferritin &gt; 500 µg/L 17 . Any medical condition , opinion Principal Investigator , may cause subject unsuitable completion study place subject potential risk study interfere study drug evaluation . Example , Uncontrolled Hypertension , Unstable Ischemic Heart Disease Uncontrolled Diabetes Mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>